Company news
Karyopharm Therapeutics Inc. news in 2021
Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.
Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories
December 20, 2021
Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition
December 10, 2021
Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors
December 5, 2021
Karyopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis
December 5, 2021
Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer
December 1, 2021
Karyopharm to Host Virtual Investor Day on December 8, 2021
November 30, 2021
Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition
November 3, 2021
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights
November 2, 2021
Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome
October 20, 2021
Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results
August 4, 2021
Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021
July 28, 2021
Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis
July 27, 2021
Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million
June 23, 2021
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress
June 8, 2021
Karyopharm Announces Key Changes to Its Commercial Leadership Team
June 7, 2021
Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets
June 2, 2021
Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
June 1, 2021
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
May 18, 2021
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
May 2, 2021
Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021
April 27, 2021
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology
April 18, 2021
Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
March 28, 2021
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
February 10, 2021
Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma
February 3, 2021
Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
January 28, 2021
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
January 10, 2021
Calls in 2021
- Karyopharm Therapeutics (NASDAQ:KPTI) Q3 2021 Earnings Call
Nov 3, 2021
Transcript - Karyopharm Therapeutics (NASDAQ:KPTI) Q2 2021 Earnings Call
Aug 5, 2021
Transcript - Karyopharm Therapeutics (NASDAQ:KPTI) Q1 2021 Earnings Call
May 3, 2021
Transcript - Karyopharm Therapeutics (NASDAQ:KPTI) Q4 2020 Earnings Call
Feb 11, 2021
Transcript
Decks in 2021
- Technical Presentation (December 2021)
Technical · 16 slides · Dec 1, 2021